RDHL News

An upfront cash infusion from a commercial asset sale sparked a massive morning rally in specialty pharma today, highlighting how non-dilutive liquidity events can rapidly re-rate microcap balance sheets. When a developer monetizes its majority stake in an approved drug to a global manufacturing partner, the market quickly rewards the immediate cash injection. RedHill Biopharma Ltd. (Nasdaq: RDHL) advanced Monday after divesting its Talicia business to a subsidiary of Apotex Health Corp. (TSX: APTX) for $18M in cash upfront, plus up to additional $35M tied to worldwide net-sales ...

An upfront cash infusion from a commercial asset sale sparked a massive morning rally in specialty pharma today, highlighting how non-dilutive liquidity events can rapidly re-rate microcap balance sheets. When a developer monetizes its majority stake in an approved drug to a global manufacturing partner, the market quickly rewards the immediate cash injection. RedHill Biopharma Ltd. (Nasdaq: RDHL) advanced Monday after divesting its Talicia business to a subsidiary of Apotex Health Corp. (TSX: APTX) for $18M in cash upfront, plus up to additional $35M tied to worldwide net-sales ...

RedHill Biopharma divests Talicia to Apotex, boosting liquidity and funding its commercial growth strategy and RHB-102 development.read more...

RedHill Biopharma (NASDAQ:RDHL) just sold the product that defined its U.S. commercial identity. RedHill announced it divested its remaining 70% stake in Talicia to a subsidiary of newly public Apotex Health (TSX:APTX) for $18 million in cash upfront plus up to $35 million in worldwide net sales milestones. Apotex already owned the other 30% after buying Cumberland’s (NASDAQ:CPIX) U.S. branded business earlier this year. The sale consolidates Talicia under one owner and gives RedHill the liquidity it says it needs to rebuild a larger gastrointestinal franchise.

Gainers Redhill Biopharma (NASDAQ:RDHL) shares increased by 96.7% to $1.3 during Monday's pre-market session. The market value of their outstanding shares is at $4.0 million. Vivos Therapeutics (NASDAQ:VVOS) stockread more...

Ebola Cases and Deaths Rapidly Mount - RedHill Updates on Opaganib Emergency Outbreak Development Ebola Cases and Deaths Rapidly Mount - RedHill Updates on Opaganib Emergency Outbreak Development PR Newswire TEL AVIV, Israel and RALEIGH, N.C., July 28, 2026 The number of confirmed Ebola cases and...

RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement PR Newswire TEL AVIV, Israel and RALEIGH, N.C., June 22, 2026 $6 million upfront with up to approximately $13.4 million of potential aggregate...

RedHill Biopharma Announces Up To $19.4 Million Private Placement RedHill Biopharma Announces Up To $19.4 Million Private Placement PR Newswire TEL AVIV, Israel & RALEIGH, N.C., June 18, 2026 $6 million upfront with up to approximately $13.4 million of potential aggregate gross proceeds upon the...

RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation PR Newswire RALEIGH, N.C. and...